Clinical Trials Browser

Uterine Cervical Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03556839 2025-01-08

BEATcc

Phase 3 Active not recruiting

410 enrolled

Gynecologic

Carcinoma, Uterine Cervical Neoplasms

NCT03946358 2024-12-20

VolATIL

Phase 2 Completed

47 enrolled

GastrointestinalGynecologicHead & Neck

Anal Canal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

NCT03340376 2024-07-03

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Phase 2 Active not recruiting

48 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT02914470 2021-10-19

PROLOG

Phase 1 Completed

12 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Clinical Trials

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

BEATcc

VolATIL

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

PROLOG